{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-24-000097","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2024-12-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.156142+00:00","generated_at":"2026-05-29T09:54:39.155525+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Keros licenses elritercept to Takeda for $200M upfront; milestones up to $1.1B","bullets":["Upfront payment of $200M; eligible for up to $370M in development/commercial milestones and $740M in sales milestones.","Tiered royalties on net sales in Territory (ex-China) from low double-digits to high teens, subject to reductions.","Elritercept in Phase 2 for MDS and myelofibrosis; Phase 3 RENEW trial for MDS to begin enrollment soon.","Keros expects upfront proceeds to extend cash runway into Q4 2028, supporting cibotercept and KER-065 programs.","Agreement effective subject to HSR Act clearance."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-24-000097","json":"https://secwatch.observer/filing/0001664710-24-000097.json","markdown":"https://secwatch.observer/filing/0001664710-24-000097.md","text":"https://secwatch.observer/filing/0001664710-24-000097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000097/0001664710-24-000097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000097/kros-20241203.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T09:54:39.155525+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}